DUBLIN, Calif., May 11 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference, being held at the Le Meridien Hotel in Monte Carlo, Monaco on Tuesday, May 16, 2006 at 11:15 a.m. CEST (5:15 a.m. EDT). Dr. Manuso will provide a brief corporate overview and discuss the Company’s recent progress.
A live webcast of Dr. Manuso’s presentation will be available on the Investor Relations section of the Company’s website at http://www.supergen.com. The webcast will be archived for 90 days.
About SuperGen
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the, discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen’s portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com .
Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications & Business Development Director of Investor Relations Tel: (925) 560-0100 x111 Tel: (212) 845-4271 E-mail: tenns@supergen.com E-mail: sharon.weinstein@eurorscg.com
SuperGen, Inc.
CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment, of SuperGen, +1-925-560-0100, ext. 111, tenns@supergen.com;Sharon Weinstein, Director of Investor Relations of Noonan Russo forSuperGen, Inc., +1-212-845-4271, sharon.weinstein@eurorscg.com
Web site: http://www.supergen.com/
